About us

ViraTherapeutics is a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies. It was previously formed as a spin-off of the Medical University of Innsbruck in April 2013.

ViraTherapeutics specializes in the development of highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. The proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed.